Justin Call

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Andres Forero‐Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub et al. · Blood · 2019 · 100 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Yonina R. Murciano‐Goroff, Rebecca S. Heist, Yasutoshi Kuboki et al. · Cancer Research · 2023 · 37 citations

Medicine, Oncology, Pharmacology +13

Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study.

Antoine Hollebecque, Yasutoshi Kuboki, Yonina R. Murciano‐Goroff et al. · Journal of Clinical Oncology · 2024 · 31 citations

Medicine, Oncology, Pharmacology +16

660MO First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)

Cesar A. Perez, Jason T. Henry, Nehal J. Lakhani et al. · Annals of Oncology · 2023 · 20 citations · Full text

Medicine, Cancer Biology, Oncology +8